In 1985, the Nobel Prize in Physiology or Medicine was awarded to Michael Brown and Joseph Goldstein for identifying the receptor that clears LDL particles from the bloodstream. High blood levels of ...
Understanding the interface between nanomaterials and lipoproteins is crucial for gaining insights into their impact on lipoprotein structure and lipid metabolism. Here, we use graphene oxide (GOs) ...
National Institute of Health (NIH) scientists have made a significant breakthrough in understanding how "bad" cholesterol, known as low-density lipoprotein-cholesterol or LDL-C, builds up in the body.
Low-density lipoprotein, known as LDL, is a complex structure with several components that allow cholesterol to circulate in the bloodstream, a watery environment. LDL is the primary mechanism used to ...
Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver. We conducted a randomized, ...
Despite decades of study, a pharmacopoeia of medicines, and untold millions in pharmaceutical research, heart disease remains the leading cause of death around the world. Excess cholesterol in ...
Michael D. Shapiro, DO, discusses how lipoproteins, chiefly LDL (low-density lipoprotein) and Lp(a) (lipoprotein a), drive atherosclerotic heart disease. This is a video synopsis/summary of an ...
National Institute of Health (NIH) scientists have made a significant breakthrough in understanding how "bad" cholesterol, known as low-density lipoprotein-cholesterol or LDL-C, builds up in the body.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results